Aeroturn Brings Enterprise-Level Security to Multi-National Biopharma Company With Installation of High Performance Turnstiles
Aeroturn LLC has announced that the company’s turnstiles were selected for deployment at multiple locations of a major Biopharma manufacturer in North America. Biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. With the current global health pandemic, the Biopharma manufacturer needed to upgrade the security at its central US location quickly and efficiently.
Over the years, Aeroturn has been instrumental in helping this Biopharma giant secure multiple campuses where security needs to be at the highest level. With a heavy focus on research and development, the Biopharma company was looking for a best-in-class turnstile solution that could operate without any downtime and secure its perimeter effectively. With major security upgrades over the years which warranted finding the best turnstile manufacturer in the industry; the decision was solely based on performance. After researching multiple vendors and receiving live product demonstrations, the physical security team knew that Aeroturn was the clear winner.
“We are proud to have been selected as the winning turnstile solution after competing against two other large well-known turnstile manufacturers,” said Michael Stoll, vice president of technical sales and marketing at Aeroturn. “Aeroturn won the initial project back in 2018 and all future installations based on superior reputation, performance specifications, durability, endurance, our 5-year warranty & zero maintenance mechanisms, and a 10 million passages guarantee.”
With a phased approach, Aeroturn won Phase I in September 2018 and deployed four lanes of its enhanced X-Wing turnstiles with custom LED’s that matched the corporate colors at the Biopharma company’s North American headquarters. Phase II consisted of an additional 11 lanes of X-Wing turnstiles that were deployed the following year at another North American campus.
After proving themselves over the course of two years, Aeroturn was selected once again in 2020 to complete Phase III with an additional 8 lanes of turnstiles and the remaining to be deployed at the end of 2020 at the same campus. Each location came with its own set of customized floor conditions, side entry cabling, and low-profile platforms when necessary; making this a customized turnstile solution. In addition, all work was performed off-hours and weekends to help minimize disruption at the facility at no additional cost to the Biopharma company.